AMYLYX PHARMACEUTICALS ($AMLX) posted quarterly earnings results on Thursday, November 6th. The company reported earnings of -$0.37 per share, beating estimates of -$0.46 by $0.09. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $AMLX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AMYLYX PHARMACEUTICALS Insider Trading Activity
AMYLYX PHARMACEUTICALS insiders have traded $AMLX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $AMLX stock by insiders over the last 6 months:
- GINA MAZZARIELLO (Chief Legal Officer) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $246,148.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AMYLYX PHARMACEUTICALS Hedge Fund Activity
We have seen 73 institutional investors add shares of AMYLYX PHARMACEUTICALS stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 3,619,300 shares (+394.7%) to their portfolio in Q2 2025, for an estimated $23,199,713
- BLACKROCK, INC. added 3,122,780 shares (+130.8%) to their portfolio in Q2 2025, for an estimated $20,017,019
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 3,102,395 shares (+54.5%) to their portfolio in Q2 2025, for an estimated $19,886,351
- FMR LLC added 1,890,031 shares (+163.2%) to their portfolio in Q2 2025, for an estimated $12,115,098
- ABERDEEN GROUP PLC removed 1,691,701 shares (-69.6%) from their portfolio in Q2 2025, for an estimated $10,843,803
- MILLENNIUM MANAGEMENT LLC removed 1,569,795 shares (-50.9%) from their portfolio in Q2 2025, for an estimated $10,062,385
- CITADEL ADVISORS LLC removed 1,514,849 shares (-54.9%) from their portfolio in Q2 2025, for an estimated $9,710,182
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AMYLYX PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $AMLX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Goldman Sachs issued a "Buy" rating on 09/16/2025
- Guggenheim issued a "Buy" rating on 09/15/2025
- B of A Securities issued a "Buy" rating on 08/28/2025
- Citigroup issued a "Buy" rating on 06/17/2025
- Mizuho issued a "Outperform" rating on 05/14/2025
To track analyst ratings and price targets for AMYLYX PHARMACEUTICALS, check out Quiver Quantitative's $AMLX forecast page.
AMYLYX PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $AMLX recently. We have seen 6 analysts offer price targets for $AMLX in the last 6 months, with a median target of $19.5.
Here are some recent targets:
- Geoff Meacham from Citigroup set a target price of $20.0 on 10/17/2025
- Joel Beatty from Baird set a target price of $19.0 on 10/16/2025
- Geoff Meacham from B of A Securities set a target price of $16.0 on 10/03/2025
- Corinne Johnson from Goldman Sachs set a target price of $20.0 on 09/16/2025
- Seamus Fernandez from Guggenheim set a target price of $25.0 on 09/15/2025
- Graig Suvannavejh from Mizuho set a target price of $8.0 on 05/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
